CELU Celularity
- 2.0400
- +0.0300+1.49%
- 1.9527
- -0.0873-4.28%
About Celularity Company
Celularity, Inc. is a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert Joseph Hariri Gordon in 2016 and is headquartered in Florham Park, NJ.
Company Profile
Company Executives
- Name
- Position
- Salary
- Dr. Robert J. Hariri, M.D.,PhD
- Chief Executive Officer and Executive Chairman of the Board
- 1.23M
- John R. Haines
- Senior Executive Vice President, General Manager and Chief Administrative Officer
- 815.82K
- David C. Beers
- Chief Financial Officer and Principal Accounting Officer
- --
- Stephen A. Brigido, D.P.M.
- President, Degenerative Disease
- --
- Dr. Peter H. Diamandis, M.D.
- Independent Director
- 326.50K
- Dr. Geoffrey Shiu Fei Ling, M.D.
- Independent Director
- 301.25K
- Richard J. Berman
- Independent Director
- --
- Diane L. Parks, M.B.A.
- Independent Director
- 322.50K
- Dean C. Kehler
- Independent Director
- 354.75K
Analysis
Price Target
No Data
No Data